Sugi Predict

Sugi Predict / Compounds / SCHEMBL279207

SCHEMBL279207

SCHEMBL279207

Nc1ncnn2cc(C(=O)O)c(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)n4)cc3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKB Q96GD4 8/20 0.43
▸ AURKA O14965 8/20 0.43
▸ KDR P35968 6/20 0.42
▸ LCK P06239 3/20 0.42
▸ FLT3 P36888 3/20 0.42
▸ NTRK1 P04629 2/20 0.42
▸ FYN P06241 2/20 0.42
▸ LYN P07948 2/20 0.42
▸ PIM1 P11309 2/20 0.42
▸ MARK3 P27448 2/20 0.42
▸ MAPK9 P45984 2/20 0.42
▸ GSK3A P49840 2/20 0.42
▸ GSK3B P49841 2/20 0.42
▸ BLK P51451 2/20 0.42
▸ RPS6KA3 P51812 2/20 0.42
▸ STK3 Q13188 2/20 0.42
▸ ROCK1 Q13464 2/20 0.42
▸ ERBB4 Q15303 2/20 0.42
▸ NTRK2 Q16620 2/20 0.42
▸ MARK2 Q7KZI7 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276193 0.88 AURKB (0.45) AURKBAURKAKDRLCKFLT3
SCHEMBL275915 0.88 BTK (0.46) AURKBAURKAKDRLCKFLT3
SCHEMBL5276553 0.88 KDR (0.51) AURKBAURKAKDRLCKFLT3
SCHEMBL5281318 0.84 KDR (0.55) AURKBAURKAKDRLCKFLT3
SCHEMBL5276575 0.83 AURKA (0.44) AURKBAURKAKDRLCKFLT3
SCHEMBL13437463 0.82 AURKA (0.44) AURKBAURKAKDRLCKFLT3
SCHEMBL275916 0.82 KDR (0.57) AURKBAURKAKDRLCKFLT3
SCHEMBL3618935 0.82 FLT1 (0.55) AURKBAURKAKDRLCKFLT3
SCHEMBL3613438 0.81 AURKB (0.44) AURKBAURKAKDRLCKFLT3
SCHEMBL5276476 0.81 RIPK1 (0.52) AURKBAURKAKDRLCKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133995-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-13 — — US disclosed
US-8133995-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-13 — — US disclosed
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis BAYER HEALTHCARE LLV (US) 2009-11-12 — — US disclosed
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis BAYER HEALTHCARE LLV (US) 2009-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis CDK4, FLT4, CDKL4 AURKB 1695/4885AURKA 1123/4885KDR 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.